Abstract. Aberrant promoter DNA methylation is a major mechanism of leukemogenesis in hematologic malignancies, including acute myeloid leukemia (AML). However, the association between promoter methylation with chemotherapeutic outcomes remains unknown. In the present study, bone marrow samples were collected prior to and following chemotherapy in 30 AML patients. Methylation-specific polymerase chain reaction technology was used to examine the promoter methylation status of adenomatous polyposis col 2 (APC2) and cytochrome P450 family 1 subfamily B polypeptide 1 (CYP1B1). The results revealed no change in the methylation status of the APC2 promoter in patients following various chemotherapy regimens. However, the methylation status of the CYP1B1 promoter changed in response to 6 different chemotherapy regimens. AML patients of the M3 subtype displayed an induction of the CYP1B1 promoter methylation levels more frequently (57.1%) than patients affected by the other subtypes (M1: 33.3%; M2: 12.5%; M4: 16.7%; M5: 0% and M6: 0%). In addition, a higher frequency of male patients (4/13) exhibited modulation of the CYP1B1 promoter methylation status compared with female patients (3/17). Furthermore, of five AML patients with a poor prognosis, two exhibited changes leading to CYP1B1 hypomethylation and two leading to CYP1B1 hypermethylation. By contrast, three other patients exhibited hypermethylation changes along with remission. This may be explained by the different chemotherapy regimens used to treat these patients or by other unknown factors. The present study revealed that CYP1B1 promoter methylation was induced during chemotherapy, whereas the APC2 promoter remained hemimethylated. Furthermore, the changes in CYP1B1 methylation were dependent on the AML subtypes and the gender of the patients.
Introduction
Promoter methylation is important in epigenetics and always leads to transcriptional silencing of tumor suppressor genes in acute myeloid leukemia (AML) (1) . Although current chemotherapy regimens result in complete remission in many cases, there is no standard and efficient therapy for refractory AML (2) . As aberrant DNA methylation is common in AML, clinical trials using epigenetically-targeted therapies have yielded particularly promising results in the treatment of hematopoietic malignancies (3) . Several demethylating agents, including azacytidine and decitabine, have been demonstrated to improve AML prognosis (4) .
Adenomatous polyposis col 2 (APC2) is a tumor suppressor gene, encoding a protein that controls the stability and nuclear export of β-catenin, which is a Wnt signaling pathway transcriptional coactivator (5) . Wnt pathway inhibitors are methylated at a high frequency in AML patients (6) . The cytochrome P450 family 1 subfamily B polypeptide 1 (CYP1B1) gene, which is a candidate target gene in numerous types of cancers, encodes a member of the cytochrome P450 enzyme superfamily. Furthermore, cytochrome P450 enzymes are involved in drug metabolism and the synthesis of cholesterol, steroids and other lipids (7) . A previous study has revealed high CYP1B1 expression in human myeloid leukemia cell lines (8) and another study identified a significant incidence of methylation in the patients with acute leukemia (9) .
Alterations in the promoter methylation status, which is considered to be an indicator of a molecular abnormality, can be used to predict the chemotherapeutic outcomes of multiple regimens towards individualized therapy. The aim of the present study was to investigate changes in the methylation APC2 and CYP1B1 methylation changes in the bone marrow of acute myeloid leukemia patients during chemotherapy Written informed consent was obtained from all patients after the possible consequences of participating in the study had been explained.
DNA extraction and bisulfite DNA modification. Genomic DNA was isolated from bone marrow nucleated cells using a nucleic acid extraction analyzer (Lab-Aid 820; Zeesan Biotech, Xiamen, China). The DNA concentration of each specimen was measured via a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Inc., Wilmington, NC, USA). All DNA samples were modified using the reagents provided in the ZYMO EZ DNA Methylation-Gold kit (Zymo Research Corp., Irvine, CA, USA). Following bisulfite treatment, the converted DNA samples were stored at -20˚C.
Methylation-specific polymerase chain reaction (MSP PCR).
Modified DNA samples were subjected to MSP using APC and CYP1B1 MSP primers (11) . Two pairs of primers were synthesized by Shanghai Sangon Biotechnology Co., Ltd.
(Shanghai, China) according to the sequences listed in Table II . Methylated primers were used to amplify methylated regions and unmethylated primers to amplify unmethylated regions. Each PCR reaction contained 1.5 µl sodium bisulfite modified DNA, 0.5 µl each primer, 10 µl Zymo TaqTM Premix (Zymo Research, Orange, CA, USA) and 7.5 µl DNAase/RNAase-free water in a final reaction volume of 20 µl. DNA amplification was performed using a Veriti ® PCR machine (Applied Biosystems, Thermo Fisher Scientific, Inc.). Thermocycling conditions were as follows: Initial denaturation step at 95˚C for 10 min followed by 35 cycles of amplification, each cycle included a denaturation step at 94˚C for 30 sec, an annealing step with a primer-specific temperature for 45 sec and an elongation step at 72˚C for 1 min. The final extension step was performed at 72˚C for 7 min. The methylation status of each sample was determined using one or two independent experiments. Water blank was used as a negative control. PCR products were analyzed using a Qsep100 DNA Analyzer (Bioptic Inc., Taiwan, China). Samples were considered as methylated or unmethylated according to the presence of clearly visible peaks by the Q-analyzer software (Fig. 1) . The sequences and details of the methylated and unmethylated primers are provided in Table II . DNA samples were randomly sequenced using the Applied Biosystems 3730 DNA Analyzer (Thermo Fisher Scientific, Inc.) to confirm complete bisulfite conversion (Fig. 2) .
Statistical analysis. Comparisons between APC2 and CYP1B1
promoter methylation were performed using the correction formula of a χ 2 test. Statistical analyses were performed using the SPSS 18.0 Evaluation version software for Windows (SPSS Inc., Chicago, IL, USA). MSP results were compared in samples pre-and post-chemotherapy. Table I , the chemotherapy agents used included Ara-C, ATRA, As 2 O 3 , HHT, G-CSF, IDA, ACLA and DNR. A total of 22 patients in remission and eight patients with a poorer prognosis were treated with these 13 agents, either in single or combined regimens.
Results

Chemotherapy. As shown in
MSP was performed on pre-and post-chemotherapy bone marrow samples from 30 AML patients in order to determine whether the chemotherapy treatment was able to alter APC2 and CYP1B1 promoter methylation levels. APC2 promoter methylation status remained unchanged by chemotherapy. In contrast, seven patients demonstrated CYP1B1 promoter changes during chemotherapy.
Regimen-based subgroup analyses of CYP1B1 promoter methylation changes in AML patients. Seven patients treated with six regimens exhibited CYP1B1 promoter methylation changes, including five samples with hypermethylation and two samples demonstrating hypomethylation. Of the five patients with induced hypermethylation, three patients in remission were treated with Ara-C, HHT + Ara-C and IDA + Ara-C + ACLA + G-CSF + HHT regimens, and two patients treated with As 2 O 3 + DNR + ATRA. Ara-C + ACLA + G-CSF regimens resulted in a poor patient prognosis. Two patients with induced hypomethylation were treated with Ara-C + ACLA + G-CSF, and IDA + Ara-C regimens and had a poorer prognosis.
Analyses of CYP1B1 promoter methylation changes in patients based on AML subtypes.
The results of the present study were obtained from three patients diagnosed with the M1 AML subtype, eight with M2, seven with M3, six with M4, three with M5 and three with M6. Outcomes associated with chemotherapy-induced CYP1B1 promoter methylation changes varied according to the subtypes. Chemotherapy-induced methylation changes were more often observed in M3 patients (57.1%, 4/7) compared with patients diagnosed with other subtypes (M1: 33.3%, 1/3; M2: 12.5%, 1/8; M4: 16.7%, 1/6; M5: 0%, 0/3; and M6: 0%, 0/3). Table I , of the 24 patients aged ≤60 years, 20 patients exhibited induced hypermethylation and four patients showed induced hypomethylation. Among the six patients aged >60 years old, five exhibited induced hypermethylation and one demonstrated induced hypomethylation. By further categorizing patients according to age, chemotherapy-induced methylation changes were observed to be more often present among AML patients >60 years of age (33.3%, 2/6) compared with patients ≤60 years of age (20.8%, 5/24). Among the patients aged ≤60 years, one patient of the M1 subtype (Ara-C + ACLA + G-CSF; aged 59 years) exhibited an induced hypermethylation and worse consequence, one patient of M3 subtype (As 2 O 3 + DNR + ATRA; aged 40 years) showed an induced hypermethylation along with a poor prognosis, two M3 patients (HHT + Ara-C; aged 59 years and Ara-C; aged 30 years) demonstrated induced hypermethylation along with remission and one patient of the M3 subtype (IDA + Ara-C; aged 42 years) exhibited induced hypomethylation along with a poor prognosis. As for patients >60 years of age, one M2 subtype patient (Ara-C + ACLA + G-CSF, aged 76 years) exhibited an induced hypomethylation along with a poor prognosis and one M4 subtype patient (IDA + A ra-C + ACLA + G-CSF + HHT, aged 67 years) demonstrated hypermethylation along with an improved prognosis. Gender-based subgroup analyses of CYP1B1 promoter methylation changes in AML patients. As shown in Table I , 4/13 male and 3/17 female patients demonstrated CYP1B1 promoter methylation status changes. Among them, one M3 subtype male patient (HHT + Ara-C) and one M4 subtype male patient (IDA + Ara-C + ACLA + G-CSF + HHT) displayed induced hypermethylation along with remission. One M3 subtype male patient (As 2 O 3 + DNR + ATRA) exhibited induced hypermethylation along with a poor prognosis, and one M2 subtype male patient (Ara-C + ACLA + G-CSF) demonstrated induced hypomethylation along with a poor prognosis. The remaining nine male patients did not exhibit any methylation changes induced by chemotherapy.
Age-based subgroup analyses of CYP1B1 promoter methylation changes in AML patients. As shown in
In the female subgroup, one M1 subtype patient (Ara-C + ACLA + G-CSF) exhibited induced hypermethylation with a poor prognosis, one M3 subtype patient (IDA + Ara-C) exhibited induced hypomethylation with a poor prognosis, and one M3 subtype patient (Ara-C) demonstrated induced hypermethylation along with remission. However, the remaining 14 female patients did not show any methylation changes following chemotherapy.
Discussion
The present study aimed to explore the chemotherapy-induced methylation changes of the APC2 and CYP1B1 promoter in bone marrow samples from AML patients and their association with the treatment outcome.
Consistent with its role in the Wnt signaling pathway, APC2 promoter methylation was associated with the progression of various cancers, particularly colorectal cancer (12) . However, APC2 methylation is rarely observed in epithelial tumors (6) . The results of the present study demonstrated that APC2 promoter methylation remained unchanged by various chemotherapy treatments.
CYP1B1 contributes to the development and progression of various diseases, including tumorigenesis and multidrug resistance (13) . CYP1B1 promoter methylation is downregulated in colorectal cancer (14) and stratifies prognosis in patients with tamoxifen-and non tamoxifen-treated breast cancer (15) . The results demonstrated that CYP1B1 promoter methylation changed following treatment with various chemotherapy regimens, indicating complex regulation of CYP1B1 methylation in the bone marrow. In addition, different AML subtypes displayed distinct responses to multiple chemotherapy regimens, which may influence the changes of CYP1B1 methylation and the outcome of chemotherapy. Among the AML subtypes, M3 patients often revealed chemotherapy-induced changes in CYP1B1 methylation. The present study demonstrated that CYP1B1 hypermethylation in M3 patients may be associated with an improved prognosis if treated with Ara-C, HHT + Ara-C or IDA + Ara-C chemotherapy regimens. This observation provides a response tendency that is potentially useful for individualized AML therapy.
The incidence rates of acute leukemia are significantly higher in males compared with females (16) . The present study demonstrated that male patients were more susceptible to induced methylation changes compared with female patients following chemotherapy. Furthermore, the CYP1B1 promoter methylation changes during chemotherapy may serve as a potential biomarker to predict the outcome of therapy in male patients.
However, there are some limitations in the present study. Firstly, a relatively small sample size was used. The sample size of 30 patients used may prevent powerful statistical significance. Therefore, a larger sample size is required to confirm our observations in the future. Secondly, a conclusion was drawn through patients treated with 13 types of chemotherapy regimens, however, future investigation with more samples and a patient cohort treated with the same chemotherapy are required. Thirdly, the main population of the present study were people from Ningbo and studies in other regions are required in order to elucidate an integrated conclusion on the association between changeable gene methylation levels and chemotherapeutic outcomes.
In conclusion, the results of the present study demonstrated that chemotherapy-induced changes in CYP1B1 promoter methylation were associated with the AML subtype, gender and age of the patients. However, future analyses on the mechanisms by which CYP1B1 promoter methylation is altered by chemotherapeutic regimens are required.
